StockData
Agenus Inc logo

Agenus Inc (AGEN) stock

AGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 3/30
$6.29−0.44 (-6.54%)

Close on Nov 16, 2026Market cap $283.18MP/E –Yield –

Agenus r&d expenses

Research and development expenses are spending on new products and technology.

Agenus's R&D Expenses for the twelve months ending Jun 30, 2026 was $57.69M, down 53.1% year over year. For fiscal 2025 it was $79.34M, down 49.0% from the year before. Over ten years it grew 1.2% a year on average. The highest annual figure on record is $234.57M in fiscal 2023.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$79.34M-49.0%
FY2024Dec 31, 2024$155.53M-33.7%
FY2023Dec 31, 2023$234.57M+25.6%
FY2022Dec 31, 2022$186.69M+4.5%
FY2021Dec 31, 2021$178.61M+25.2%
FY2020Dec 31, 2020$142.62M-15.3%
FY2019Dec 31, 2019$168.34M+35.1%
FY2018Dec 31, 2018$124.60M+7.3%
FY2017Dec 31, 2017$116.13M+22.3%
FY2016Dec 31, 2016$94.97M+34.8%
FY2015Dec 31, 2015$70.44M+215.2%
FY2014Dec 31, 2014$22.35M+71.8%
FY2013Dec 31, 2013$13.01M+23.1%
FY2012Dec 31, 2012$10.56M-4.2%
FY2011Dec 31, 2011$11.02M-14.4%
FY2010Dec 31, 2010$12.88M-23.8%
FY2009Dec 31, 2009$16.90M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$14.76M-44.7%
Q1 FY2026Mar 31, 2026$11.82M-45.1%
Q4 FY2025Dec 31, 2025$7.51M-77.8%
Q3 FY2025Sep 30, 2025$23.60M-42.5%
Q2 FY2025Jun 30, 2025$26.71M-27.4%
Q1 FY2025Mar 31, 2025$21.52M-51.0%
Q4 FY2024Dec 31, 2024$33.78M-49.4%
Q3 FY2024Sep 30, 2024$41.06M-20.2%
Q2 FY2024Jun 30, 2024$36.77M-38.0%
Q1 FY2024Mar 31, 2024$43.93M-23.1%
Q4 FY2023Dec 31, 2023$66.72M+25.2%
Q3 FY2023Sep 30, 2023$51.44M+11.8%
Q2 FY2023Jun 30, 2023$59.29M+31.9%
Q1 FY2023Mar 31, 2023$57.12M+34.6%
Q4 FY2022Dec 31, 2022$53.28M-0.4%
Q3 FY2022Sep 30, 2022$46.01M+7.2%
Q2 FY2022Jun 30, 2022$44.96M-1.2%
Q1 FY2022Mar 31, 2022$42.44M+15.7%
Q4 FY2021Dec 31, 2021$53.49M+50.4%
Q3 FY2021Sep 30, 2021$42.94M+33.6%
Q2 FY2021Jun 30, 2021$45.51M+18.0%
Q1 FY2021Mar 31, 2021$36.68M+0.9%
Q4 FY2020Dec 31, 2020$35.57M-3.4%
Q3 FY2020Sep 30, 2020$32.13M-30.3%
Q2 FY2020Jun 30, 2020$38.55M-14.8%
Q1 FY2020Mar 31, 2020$36.36M-9.4%
Q4 FY2019Dec 31, 2019$36.83M+2.2%
Q3 FY2019Sep 30, 2019$46.13M+54.5%
Q2 FY2019Jun 30, 2019$45.24M+54.6%
Q1 FY2019Mar 31, 2019$40.13M+36.3%
Q4 FY2018Dec 31, 2018$36.03M+13.0%
Q3 FY2018Sep 30, 2018$29.85M+15.8%
Q2 FY2018Jun 30, 2018$29.27M+13.4%
Q1 FY2018Mar 31, 2018$29.44M-9.8%
Q4 FY2017Dec 31, 2017$31.87M+22.7%
Q3 FY2017Sep 30, 2017$25.79M+19.5%
Q2 FY2017Jun 30, 2017$25.82M–
Q1 FY2017Mar 31, 2017$32.64M–
Q4 FY2016Dec 31, 2016$25.98M–
Q3 FY2016Sep 30, 2016$21.59M–

More Agenus figures

See a number that looks wrong?